This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Benzodiazepine Safety: Mortality Risk or Multiple Chronic Disease Comorbidity?

Robert A. Rosenheck, MD, and Mehmet Sofuoglu, MD, PhD

Published: May 25, 2016

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Several studies in recent years have suggested increased mortality among patients diagnosed with schizophrenia and treated with benzodiazepines. In this issue, Fontanella et al add to this literature with the first US study of this kind, examining data from more than 18,000 Ohio Medicaid patients diagnosed with schizophrenia who were treated between 2006 and 2013. Patients treated with benzodiazepines without a co-prescribed antipsychotic showed a 3-fold greater risk of dying (hazard ratio [HR] = 3.08), but, curiously, patients treated with benzodiazepines with antipsychotics showed a notably lower risk of about half the magnitude (HR = 1.48).

Related Articles

Volume: 77

Quick Links: